| Price | $11.70 |
| Year Range | $8.56 – $14.21 |
| Market Cap | $63M |
| Industry | Biotechnology |
What Is MiNK Therapeutics’s AI Stock Analysis?
MiNK Therapeutics’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks MiNK Therapeutics’s momentum in near-real time.
MiNK Therapeutics (INKT) has an AltIndex AI Score of 55/100, currently a Hold signal. The AI Score distills MiNK Therapeutics's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
MiNK Therapeutics’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of MiNK Therapeutics — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving INKT’s AI Score?
Fundamentals
Net income for the last quarter was $-3.1M. This represents a decrease of 14.07% compared to the quarter before it, indicating a need for concern. Compared to the same quarter last year, there is an increase of -26.18%, suggesting positive year-over-year growth. Ebitda for the last quarter was $-3.2M. This represents a decrease of 19.45% compared to the quarter before it, indicating a need for concern. Compared to the same quarter last year, there is an increase of -22.83%, suggesting positive year-over-year growth.
See MiNK Therapeutics’s earnings and insider transactions.
Technicals
Today's stock price is $11.70. This is an increase of 0.52% compared to a month ago, indicating a positive short-term trend. However, compared to a year ago, there is a decrease of 19.81%, which could be a cause for long-term concern. The trend is bearish. The current SMA10 is $12.26, which is lower than the previous SMA10 of $12.31. This suggests a potential downward trend in price movement. The RSI is 43, indicating a neutral condition.
See the full technical analysis and price prediction.
Alternative data
The business outlook among employees at MiNK Therapeutics is low (an estimate of only 0% of employees have a positive outlook), a concerning sign. MiNK Therapeutics has an estimate of 2,000 visitors to their webpage. The number of visitors is down by -33% in the last couple of months, a worrisome trend as this can indicate a loss in customers.
Explore MiNK Therapeutics’s job postings, web traffic and app downloads.
Frequently Asked Questions: MiNK Therapeutics AI Stock Analysis
MiNK Therapeutics's AltIndex AI Score is 55/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates MiNK Therapeutics a Hold (55/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of MiNK Therapeutics — company overview, fundamentals, technicals and alternative data, with a recommendation. See the INKT AI Score or sign up to read the full thesis.
